发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-03-18 DOI: 10.1080/1750743X.2025.2478804
Markéta Šťastná-Marková, Petr Hainz, Jitka Kryštofová, Jana Macková, Kateřina Roubalová, Jan Vydra, Šárka Němečková
{"title":"Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT.","authors":"Markéta Šťastná-Marková, Petr Hainz, Jitka Kryštofová, Jana Macková, Kateřina Roubalová, Jan Vydra, Šárka Němečková","doi":"10.1080/1750743X.2025.2478804","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2478804","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to examine changes in the repertoire of functional T-cells specific for six leukemia-associated antigens (LAA), including WT1, PRAME, MUC1, CCNA1, NPM1, and NPM1c, during immune reconstitution following allogeneic transplantation of hematopoietic stem cells (HSCT) in patients with acute myeloid leukemia.</p><p><strong>Patients & methods: </strong>LAA-specific T cell response was measured by ELISPOT- IFNγ and intracellular cytokine staining in 47 patients before starting conditioning therapy (baseline) and 7 months after HSCT.</p><p><strong>Results: </strong>The positive cumulative LAA-specific T cell response before HSCT was associated with a decreased risk of relapse after HSCT. The prevalent genetic aberration - an internal tandem duplication of Fms 3 - related receptor tyrosine kinase, which has been previously implicated in immune escape mechanisms, is presented here for the first time as a factor associated with the absence of an adaptive T cell response against multiple LAAs. T-cell specific responses against wild-type and mutated NPM1 antigens were less frequent in the study cohort and did not correlate with mutations in the NPM1 gene.</p><p><strong>Conclusions: </strong>Our results showed that the T-cell response to LAA can be reconstituted after HSCT. Measurement of functional pre-transplant T-cell responses against multiple LAAs could help to find patients with an increased risk of relapse.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":2.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-03-18 DOI: 10.1080/1750743X.2025.2478814
Fahimeh Ezzatizadeh, Azam Bolhassani, Fattah Sotoodehnejad Nematalahi, Abolfazl Fateh
{"title":"Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates.","authors":"Fahimeh Ezzatizadeh, Azam Bolhassani, Fattah Sotoodehnejad Nematalahi, Abolfazl Fateh","doi":"10.1080/1750743X.2025.2478814","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2478814","url":null,"abstract":"<p><strong>Aim: </strong>This study investigated the potential of HPV16 E5 oncoprotein-modified tumor cell lysate (TCL-E5) and dendritic cells (DCs) pulsed with TCL-E5 (TCL-E5-pulsed DCs) to enhance antitumor immunity in a murine model.</p><p><strong>Materials and methods: </strong>For generation of TCL-E5, TC1 tumor cells were transduced with lentiviral particles harboring E5 protein. Moreover, the cell supernatants were prepared from DCs pulsed with TCL-E5. Their immunological responses and antitumor effects were investigated in a mouse model.</p><p><strong>Results: </strong>The TCL-E5-pulsed DCs regimen could direct immunity toward Th1 and CTL responses, leading to tumor volume reduction and high percentage of tumor-free mice.</p><p><strong>Conclusion: </strong>The TCL-pulsed DCs regimen could not induce significant antitumor effects compared to TCL-E5-pulsed-DCs regimen indicating main role of E5 in vaccine development.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-03-18 DOI: 10.1080/1750743X.2025.2478808
Shravan Leonard-Murali, Udai S Kammula
{"title":"Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma.","authors":"Shravan Leonard-Murali, Udai S Kammula","doi":"10.1080/1750743X.2025.2478808","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2478808","url":null,"abstract":"<p><p>Adoptive transfer of tumor infiltrating lymphocytes (TIL-ACT) is a personalized cancer therapy that harnesses the anti-tumor activity of tumor resident T cells through <i>ex vivo</i> activation and expansion. This therapy involves the infusion of a single dose of <i>ex vivo</i> expanded TIL together with high dose IL-2 following a preparative lymphodepleting chemotherapy. The United States Food and Drug Administration approved lifileucel in 2024 as the first autologous TIL product for patients with advanced cutaneous melanoma (CM), adding to the list of approved immunotherapies for this highly immunogenic cancer. However, the role for TIL-ACT in other solid tumors is unclear, especially for poorly immunogenic cancers with low tumor mutational burden. In this review, we describe the historical development of TIL-ACT, summarize the clinical results in advanced CM, and describe the novel application of TIL-ACT to metastatic uveal melanoma (UM), a prototypic immunotherapy-resistant solid tumor. We will highlight key biologic differences between CM and UM, their consequential influence on the manufacturing of UM-specific TIL products, and the development of novel biomarkers for precision TIL-ACT for metastatic UM.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-03-14 DOI: 10.1080/1750743X.2025.2479410
Afroditi Ziogou, Alexios Giannakodimos, Ilias Giannakodimos, Dimitrios Schizas, Nikolaos Charalampakis
{"title":"Effect of <i>Helicobacter Pylori</i> infection on immunotherapy for gastrointestinal cancer: a narrative review.","authors":"Afroditi Ziogou, Alexios Giannakodimos, Ilias Giannakodimos, Dimitrios Schizas, Nikolaos Charalampakis","doi":"10.1080/1750743X.2025.2479410","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2479410","url":null,"abstract":"<p><p>Immunotherapy for gastrointestinal cancers has elicited considerable amount of attention as a viable therapeutic option for several cancer types. Gut microbiome as a whole plays a critical role in shaping immune responses and influencing cancer progression. Recent evidence suggests that <i>Helicobacter pylori</i> (<i>H. pylori</i>), may influence immunotherapy efficacy by modulating the tumor microenvironment. Infection with <i>H</i>. <i>pylori</i> is common as it affects approximately 50% of the global population and remains the leading risk factor for gastric cancer. Interestingly, recent clinical and preclinical data has associated <i>H. pylori</i> with colorectal cancer carcinogenesis. Gut microbiome appears to be a modulator of the relationship between the immune system, gastrointestinal cancer development and existing therapies. Infection with <i>H. pylori</i> may affect immunotherapy results in both gastroesophageal and colorectal cancer; favorable results were noticed in <i>H. pylori</i> positive patients with gastric cancer, while in colorectal cancer patients the pathogen seemed to impede immunotherapy's action. This article aims to review current data on the role of <i>H. pylori</i> in triggering gastric inflammation and cancer, as well as its potential involvement in colorectal cancer development. Additionally, it seeks to highlight the impact of <i>H. pylori</i> infection on the response to immunotherapy in gastrointestinal cancers.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid biopsy for guiding breast cancer immunotherapy.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-03-14 DOI: 10.1080/1750743X.2025.2479426
Emanuela Fina, Elsa Vitale, Simona De Summa, Gennaro Gadaleta-Caldarola, Stefania Tommasi, Raffaella Massafra, Oronzo Brunetti, Alessandro Rizzo
{"title":"Liquid biopsy for guiding breast cancer immunotherapy.","authors":"Emanuela Fina, Elsa Vitale, Simona De Summa, Gennaro Gadaleta-Caldarola, Stefania Tommasi, Raffaella Massafra, Oronzo Brunetti, Alessandro Rizzo","doi":"10.1080/1750743X.2025.2479426","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2479426","url":null,"abstract":"<p><p>Liquid biopsy is a laboratory test used to detect and analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and other tumor-derived components, in a blood sample. In the context of breast cancer (BC), liquid biopsies hold significant promise for guiding the use of immune checkpoint inhibitors and immune-based combinations, offering real-time insights into tumor dynamics, treatment response, and resistance mechanisms. This review explores the role of liquid biopsy in BC immunotherapy, focusing on its applications, benefits, issues, and current and future research directions.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-03-14 DOI: 10.1080/1750743X.2025.2478811
Siqi Qiu, Zhipeng Zong, Kang He
{"title":"Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.","authors":"Siqi Qiu, Zhipeng Zong, Kang He","doi":"10.1080/1750743X.2025.2478811","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2478811","url":null,"abstract":"<p><p>Hepatic angiosarcoma is a rare yet aggressive malignancy, which is prone to misdiagnosis due to the lack of specific molecular and radiological characteristics. The treatment regimens remain controversial and disappointing. Randomized clinical trials are limited due to the rarity of this specific aggressive malignancy. Independent case reports or series can provide relevant references for treatment. We reported the very first hepatic angiosarcoma received Atezolizumab and Bevacizumab as a first-line treatment prior to liver transplantation, which resulted in a partial pathological response under specific molecular mutations. This case illustrates the potential role of immune checkpoint inhibitor combined with anti-angiogenic therapy as an off-label treatment option warranting further investigation.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-4"},"PeriodicalIF":2.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-03-07 DOI: 10.1080/1750743X.2025.2473305
Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Krishnavathana Varatharajalu, Anusha Thomas, Yinghong Wang
{"title":"Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management.","authors":"Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Krishnavathana Varatharajalu, Anusha Thomas, Yinghong Wang","doi":"10.1080/1750743X.2025.2473305","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2473305","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment by boosting the immune system's ability to target tumors. However, they can also cause serious side effects, particularly in the digestive system. These include immune-related diarrhea, inflammation of the intestines and, less commonly, inflammation of the stomach or esophagus. This review underscores the importance of early detection, accurate diagnosis, and timely treatment to improve patient outcomes. It also highlights the need for further research to develop strategies to reduce gastrointestinal toxicities and enhance the overall effectiveness of ICIs in cancer therapy.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapies for prevention and treatment of type 1 diabetes.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-03-04 DOI: 10.1080/1750743X.2025.2473311
Rebecca Jeun
{"title":"Immunotherapies for prevention and treatment of type 1 diabetes.","authors":"Rebecca Jeun","doi":"10.1080/1750743X.2025.2473311","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2473311","url":null,"abstract":"<p><p>Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing β-cells of the pancreatic islets necessitating lifelong insulin therapy. Despite significant advancements in diabetes technology with increasingly sophisticated methods of insulin delivery and glucose monitoring, people with T1D remain at risk of severe complications like hypoglycemia and diabetic ketoacidosis. There has long been an interest in altering the immune response in T1D to prevent or cure T1D across its various stages with limited efficacy. This review highlights immunomodulatory approaches over the years including the anti-CD3 monoclonal antibody teplizumab which is now approved to delay onset of T1DM and other interventions under current investigation.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-02-24 DOI: 10.1080/1750743X.2025.2459053
Victoria P Werth, Richard A Furie, Juanita Romero-Diaz, Sandra Navarra, Kenneth Kalunian, Ronald F van Vollenhoven, Filippa Nyberg, Benjamin H Kaffenberger, Saira Z Sheikh, Goran Radunovic, Xiaobi Huang, Hua Carroll, Himanshu Naik, Francois Gaudreault, Adam Meyers, Cristina Musselli, Nathalie Franchimont, Catherine Barbey
{"title":"Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary.","authors":"Victoria P Werth, Richard A Furie, Juanita Romero-Diaz, Sandra Navarra, Kenneth Kalunian, Ronald F van Vollenhoven, Filippa Nyberg, Benjamin H Kaffenberger, Saira Z Sheikh, Goran Radunovic, Xiaobi Huang, Hua Carroll, Himanshu Naik, Francois Gaudreault, Adam Meyers, Cristina Musselli, Nathalie Franchimont, Catherine Barbey","doi":"10.1080/1750743X.2025.2459053","DOIUrl":"10.1080/1750743X.2025.2459053","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.7,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary.
IF 2.7 4区 医学
Immunotherapy Pub Date : 2025-02-24 DOI: 10.1080/1750743X.2025.2459054
Richard A Furie, Ronald F van Vollenhoven, Kenneth Kalunian, Sandra Navarra, Juanita Romero-Diaz, Victoria Werth, Xiaobi Huang, Hua Carroll, Adam Meyers, Cristina Musselli, Nathalie Franchimont, Catherine Barbey
{"title":"Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary.","authors":"Richard A Furie, Ronald F van Vollenhoven, Kenneth Kalunian, Sandra Navarra, Juanita Romero-Diaz, Victoria Werth, Xiaobi Huang, Hua Carroll, Adam Meyers, Cristina Musselli, Nathalie Franchimont, Catherine Barbey","doi":"10.1080/1750743X.2025.2459054","DOIUrl":"10.1080/1750743X.2025.2459054","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.7,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信